Epidemiological Trends and Economic Burden of Genital Warts in Dutch Primary Care
Preprint
Abstract
Background: This study aims to describe the epidemiological trends and estimate the economic burden of genital warts (GW) in Dutch primary care. Methods: A retrospective, non-interventional, multiyear study (2011-2021) was performed using data from the Nivel Primary Care Database. Changes in incidence by age group, sex, and level of urbanisation of individuals with GW and associated healthcare resource use (general practitioner consultations, prescribed medication, and referrals) were estimated over the 11-year period. Total annual healthcare costs and cost per incident case were estimated via a bottom-up gross costing approach. Results: Between 2011 and 2021, GW incidence increased, which was especially seen in men (from 2.0 to 3.5 per 1 000 inhabitants) and to a lesser extent in women (from 1.9 to 2.1 per 1 000 inhabitants). GW incidence was most common in age group 20-29 years (men: 43.6%; women: 50.7%) and highly urbanised areas. Medication was prescribed in 61.4% of GW cases, and 5.4% of GW patients were referred to secondary care. Total costs in Dutch primary care increased by 108% from EUR 2.3 million in 2011 to EUR 4.9 million in 2021. The cost per incident case also showed an increasing trend from EUR 72 in 2011 to EUR 99 in 2021. Referrals to secondary care resulted in a 14-30% increase of total costs. Conclusions: This study provides novel insights into recent epidemiological trends of GW and its associated costs in Dutch primary care. Incidence especially increased among men and total annual costs of GW in primary care doubled between 2011 and 2021.Keywords
This publication has 29 references indexed in Scilit:
- Partial Protective Effect of Bivalent Human Papillomavirus 16/18 Vaccination Against Anogenital Warts in a Large Cohort of Dutch Primary Care PatientsClinical Infectious Diseases, 2020
- A general framework for classifying costing methods for economic evaluation of health careThe European Journal of Health Economics, 2020
- Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysisThe Lancet, 2019
- Medical Care Costs Associated with Genital Warts for Commercially Insured US PatientsPharmacoEconomics, 2018
- Annual prevalence and economic burden of genital warts in Korea: Health Insurance Review and Assessment (HIRA) service data from 2007 to 2015Epidemiology and Infection, 2017
- Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional studyThe Lancet Infectious Diseases, 2017
- Effectiveness of HPV vaccines against genital warts in women from Valencia, SpainVaccine, 2017
- No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitorsJournal of Infection, 2017
- Rates and predictors of genital warts burden in the Czech populationInternational Journal of Infectious Diseases, 2015
- A retrospective analysis of costs and patterns of treatment for external genital warts in the NetherlandsClinical Therapeutics, 2002